Identification

Name
Benazepril
Accession Number
DB00542  (APRD00063)
Type
Small Molecule
Groups
Approved, Investigational
Description

Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.

Structure
Thumb
Synonyms
  • Bénazépril
  • Benazepril
  • Benazeprilum
External IDs
CGS-14824A
Product Ingredients
IngredientUNIICASInChI Key
Benazepril hydrochlorideN1SN99T69T86541-74-4VPSRQEHTHIMDQM-FKLPMGAJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenazeprilTablet5 mgOralAa Pharma Inc2007-05-15Not applicableCanada
BenazeprilTablet20 mgOralAa Pharma Inc2006-03-24Not applicableCanada
BenazeprilTablet10 mgOralAa Pharma Inc2007-05-15Not applicableCanada
LotensinTablet20 mg/1OralNovartis1991-06-252016-02-01Us
LotensinTablet40 mg/1OralValidus Pharmaceuticals1991-06-21Not applicableUs
LotensinTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1991-06-252016-12-21Us
LotensinTablet20 mg/1OralPhysicians Total Care, Inc.1994-03-23Not applicableUs
LotensinTablet5 mg/1OralPhysicians Total Care, Inc.1996-12-30Not applicableUs
LotensinTablet20 mg/1OralValidus Pharmaceuticals1991-06-21Not applicableUs
LotensinTablet10 mg/1OralPhysicians Total Care, Inc.2003-11-04Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenazeprilTablet, coated40 mg/1OralInternational Laboratories, Llc2013-09-192018-06-08Us00093 5127 01 nlmimage10 7c233e09
BenazeprilTablet20 mg/1OralStat Rx USA2010-02-022018-02-08Us65162 0753 10 nlmimage10 7a3a3d61
Benazepril HClTablet10 mg/1OralNorthwind Pharmaceuticals2016-06-23Not applicableUs
Benazepril hydrochlorideTablet, film coated20 mg/1OralNorthwind Pharmaceuticals2014-05-30Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralMajor2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, coated5 mg/1OralSolco healthcare U.S., LLC2014-01-01Not applicableUs43547 0335 10 nlmimage10 7e463f51
Benazepril HydrochlorideTablet10 mg/1OralAv Kare, Inc.2010-07-29Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralProficient Rx LP2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralPreferreed Pharmaceuticals Inc.2010-09-06Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AmlobenzBenazepril hydrochloride (20 mg/1) + Amlodipine besylate (10 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0341 01 nlmimage10 c238e107
AmlobenzBenazepril hydrochloride (10 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0339 01 nlmimage10 6d03b6bd
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (10 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralTeva2007-05-18Not applicableUs00093 7371 01 nlmimage10 ce19671b
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (10 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralNucare Pharmaceuticals, Inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (10 mg/1) + Amlodipine besylate (2.5 mg/1)CapsuleOralMylan Pharmaceuticals2012-02-20Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (20 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralPd Rx Pharmaceuticals, Inc.2007-05-18Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (20 mg/1) + Amlodipine besylate (10 mg/1)CapsuleOralActavis Pharma Company2010-10-13Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (10 mg/1) + Amlodipine besylate (2.5 mg/1)CapsuleOralNu Care Pharmaceuticals,inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (20 mg/1) + Amlodipine besylate (10 mg/1)CapsuleOralbryant ranch prepack2007-05-18Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril hydrochloride (20 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralA S Medication Solutions2012-02-202017-06-20Us00378 6897 01 nlmimage10 834d41ba
International/Other Brands
Briem (Pierre Fabre (France)) / Cibacen (Novartis (Belgium, Philippines, Switzerland, Turkey), Meda (Denmark, Germany, Greece, Ireland, Italy, Netherlands, Spain)) / Cibacen WS / Cibacene (Meda (France))
Categories
UNII
UDM7Q7QWP8
CAS number
86541-75-5
Weight
Average: 424.4895
Monoisotopic: 424.199822016
Chemical Formula
C24H28N2O5
InChI Key
XPCFTKFZXHTYIP-PMACEKPBSA-N
InChI
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
IUPAC Name
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
SMILES
[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC

Pharmacology

Indication

For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Associated Conditions
Pharmacodynamics

Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.

Mechanism of action

Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.

Volume of distribution
Not Available
Protein binding

benazepril, 97%; benazeprilat, 95%

Metabolism

Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat. Benazepril and benazeprilat may be conjugated to glucuronic acid prior to urinary excretion.

Route of elimination

Benazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects.

Half life

10-11 hours

Clearance
  • 0.35 L/hr/kg [pediatric hypertensive patients receiving multiple daily doses of Benazepril hydrochloride 0.1 - 0.5 mg/kg]
  • 0.13 L/hr/kg [healthy adults receiving a single dose of 10 mg]
Toxicity

Most likely symptom of overdosage is severe hypotension. Most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Benazepril Action PathwayDrug action
Benazepril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Benazepril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Benazepril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Benazepril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Benazepril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Benazepril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Benazepril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Benazepril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Benazepril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Benazepril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Benazepril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Benazepril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Benazepril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Benazepril.Approved
AloxiprinThe therapeutic efficacy of Benazepril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Benazepril.Approved, Illicit, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Benazepril.Experimental, Investigational
AmifostineBenazepril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Benazepril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Benazepril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Benazepril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Benazepril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Benazepril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Benazepril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Benazepril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Benazepril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Benazepril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Benazepril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Benazepril.Approved, Illicit, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Benazepril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Benazepril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Benazepril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Benazepril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Benazepril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Benazepril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Benazepril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Benazepril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Benazepril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Benazepril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Benazepril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Benazepril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Benazepril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Benazepril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Benazepril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Benazepril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Benazepril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benazepril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Benazepril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Benazepril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Benazepril.Experimental
BarbitalBarbital may increase the hypotensive activities of Benazepril.Illicit
BarnidipineBenazepril may increase the antihypertensive activities of Barnidipine.Approved
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Benazepril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Benazepril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Benazepril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Benazepril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Benazepril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Benazepril.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Benazepril.Approved
BepridilBenazepril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Benazepril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Benazepril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Benazepril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Benazepril.Experimental
BimatoprostBenazepril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BoceprevirThe serum concentration of Benazepril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Benazepril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Benazepril.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Benazepril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Benazepril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Benazepril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Benazepril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Benazepril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Benazepril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Benazepril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Benazepril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benazepril.Approved, Investigational
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Benazepril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Benazepril.Approved
CadralazineCadralazine may increase the hypotensive activities of Benazepril.Experimental
CafedrineBenazepril may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Benazepril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Benazepril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benazepril.Approved
Carbaspirin calciumThe therapeutic efficacy of Benazepril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Benazepril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Benazepril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Benazepril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Benazepril.Approved
CarvedilolBenazepril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Benazepril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Benazepril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Benazepril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Benazepril.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benazepril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Benazepril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benazepril.Approved
CilazaprilBenazepril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Benazepril.Approved, Investigational
CiprofloxacinThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benazepril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Benazepril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Benazepril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Benazepril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Benazepril.Approved
CloranololBenazepril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Benazepril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Benazepril.Approved, Investigational
CryptenamineBenazepril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Benazepril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Benazepril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Benazepril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Benazepril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Benazepril.Approved, Investigational
DelaprilBenazepril may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Benazepril.Approved
DersalazineThe therapeutic efficacy of Benazepril can be decreased when used in combination with Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Benazepril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Benazepril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineBenazepril may increase the hypotensive activities of Dexniguldipine.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Benazepril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Benazepril.Experimental
DiclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Benazepril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineBenazepril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benazepril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Benazepril.Experimental
DiflunisalThe therapeutic efficacy of Benazepril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benazepril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Benazepril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benazepril.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Benazepril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Benazepril.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Dipyridamole.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Benazepril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Benazepril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Benazepril.Approved, Investigational
DrospirenoneBenazepril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Benazepril.Withdrawn
DuloxetineBenazepril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Benazepril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Benazepril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Benazepril.Investigational
EfonidipineBenazepril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Empagliflozin.Approved
EnalaprilatBenazepril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Benazepril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Benazepril.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Benazepril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Benazepril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Benazepril.Approved
EpoprostenolBenazepril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benazepril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Benazepril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Benazepril.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Benazepril.Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Benazepril.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Benazepril.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Benazepril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Benazepril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Benazepril.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Benazepril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Benazepril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Benazepril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Benazepril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Benazepril.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Benazepril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Benazepril.Experimental
FelodipineBenazepril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Benazepril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Benazepril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Benazepril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Benazepril.Experimental
Ferulic acidBenazepril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benazepril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Benazepril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Benazepril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Benazepril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Benazepril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Benazepril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Benazepril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Benazepril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Benazepril.Approved, Vet Approved
GarlicThe serum concentration of Benazepril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Benazepril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzBenazepril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Benazepril.Approved
GuanazodineBenazepril may increase the hypotensive activities of Guanazodine.Experimental
GuanfacineGuanfacine may increase the hypotensive activities of Benazepril.Approved, Investigational
GuanoxabenzBenazepril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBenazepril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Benazepril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Benazepril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Heparin.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Benazepril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Benazepril.Investigational
HydralazineHydralazine may increase the hypotensive activities of Benazepril.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Benazepril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Benazepril.Approved, Investigational
IbuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Benazepril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Benazepril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Benazepril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Benazepril.Approved, Investigational
ImidaprilBenazepril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Benazepril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Benazepril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Benazepril.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Benazepril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benazepril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Benazepril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Benazepril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Benazepril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Benazepril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Benazepril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benazepril.Approved, Investigational
IronIron can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Benazepril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Benazepril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Benazepril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Benazepril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Benazepril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Benazepril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Benazepril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Benazepril.Approved, Vet Approved
KetorolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Benazepril.Approved
LabetalolBenazepril may increase the hypotensive activities of Labetalol.Approved
LacidipineBenazepril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Benazepril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostBenazepril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Benazepril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Benazepril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Benazepril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Benazepril.Approved, Investigational
LevodopaBenazepril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Benazepril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Benazepril.Approved
LinsidomineBenazepril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilBenazepril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benazepril.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Benazepril.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Benazepril.Experimental
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Benazepril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Benazepril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Benazepril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Benazepril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Benazepril.Approved, Investigational
MacitentanBenazepril may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benazepril.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineBenazepril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Benazepril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Benazepril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Benazepril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benazepril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Benazepril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Benazepril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Benazepril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Benazepril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Benazepril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Benazepril.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Benazepril.Approved
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Benazepril.Approved
Methyl salicylateThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Benazepril.Approved, Vet Approved
MethyldopaBenazepril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Benazepril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Benazepril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Benazepril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Benazepril.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Benazepril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Benazepril.Approved, Investigational
MibefradilBenazepril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Benazepril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Benazepril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Benazepril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Benazepril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Benazepril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Benazepril.Approved, Investigational
MoexiprilBenazepril may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Benazepril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Benazepril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Benazepril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Benazepril.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benazepril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benazepril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Benazepril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Benazepril.Approved
NadololBenazepril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Benazepril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Benazepril.Approved
NaftopidilBenazepril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Benazepril.Approved, Vet Approved
NebivololBenazepril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Benazepril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Benazepril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Benazepril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Benazepril.Withdrawn
NicardipineBenazepril may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Benazepril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Benazepril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benazepril.Approved
NiguldipineBenazepril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBenazepril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Benazepril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Benazepril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Benazepril.Approved
NitrendipineBenazepril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Benazepril.Approved
NitroaspirinThe therapeutic efficacy of Benazepril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Benazepril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Benazepril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Benazepril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Benazepril.Approved
ObinutuzumabBenazepril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Benazepril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benazepril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benazepril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Benazepril.Approved
OmeprazoleOmeprazole can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Benazepril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Benazepril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Benazepril.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benazepril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Benazepril.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Benazepril.Experimental, Nutraceutical
PapaverineThe risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Benazepril.Approved
PargylinePargyline may increase the hypotensive activities of Benazepril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Benazepril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Benazepril can be decreased when used in combination with Patent Blue.Approved
PenbutololBenazepril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
PentoliniumBenazepril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Benazepril.Approved, Investigational
PerindoprilBenazepril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Benazepril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Benazepril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
PhentolamineBenazepril may increase the hypotensive activities of Phentolamine.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Benazepril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Benazepril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benazepril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Benazepril.Approved
PindololBenazepril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Benazepril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Benazepril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Benazepril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Benazepril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benazepril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Benazepril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Benazepril.Withdrawn
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Benazepril.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Benazepril.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Benazepril.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Benazepril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Benazepril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Benazepril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Benazepril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Benazepril.Approved
PregabalinThe risk or severity of angioedema can be increased when Benazepril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Benazepril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Benazepril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Benazepril.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Benazepril.Approved, Investigational, Vet Approved
PropranololBenazepril may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Benazepril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Benazepril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Benazepril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Benazepril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Benazepril.Approved
QuinineQuinine may increase the hypotensive activities of Benazepril.Approved
RamiprilRamipril may increase the hypotensive activities of Benazepril.Approved
RasagilineRasagiline may increase the hypotensive activities of Benazepril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benazepril.Approved
RemikirenRemikiren may increase the hypotensive activities of Benazepril.Approved
ReserpineReserpine may increase the hypotensive activities of Benazepril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benazepril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Benazepril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Benazepril.Approved
RisperidoneBenazepril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabBenazepril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Benazepril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Benazepril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benazepril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Benazepril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Benazepril is combined with Sacubitril.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Benazepril.Approved
Salicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Benazepril.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Benazepril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benazepril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Benazepril.Investigational
SaxagliptinThe risk or severity of angioedema can be increased when Saxagliptin is combined with Benazepril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Benazepril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
SelexipagBenazepril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Benazepril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Benazepril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Benazepril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benazepril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Benazepril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Benazepril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Benazepril.Approved, Investigational
SitagliptinThe risk or severity of angioedema can be increased when Sitagliptin is combined with Benazepril.Approved, Investigational
SitaxentanBenazepril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Benazepril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of nephrotoxicity can be increased when Benazepril is combined with Sodium phosphate, monobasic.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.Approved
SpiraprilBenazepril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Benazepril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Benazepril.Investigational
St. John's WortThe metabolism of Benazepril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Benazepril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benazepril.Approved, Investigational
SulfasalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Benazepril.Approved
SulindacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Benazepril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Benazepril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Benazepril.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Benazepril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
TalinololBenazepril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Benazepril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Benazepril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benazepril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benazepril.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Benazepril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Benazepril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Benazepril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Benazepril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Benazepril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Benazepril.Approved
TetrahydropalmatineBenazepril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Benazepril.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Benazepril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benazepril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Benazepril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Benazepril.Approved
TimololTimolol may increase the hypotensive activities of Benazepril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Benazepril.Investigational
TipranavirThe serum concentration of Benazepril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Benazepril.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benazepril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Benazepril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benazepril.Approved
TolonidineBenazepril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Benazepril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Benazepril.Approved
TorasemideTorasemide may increase the hypotensive activities of Benazepril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Benazepril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Benazepril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Benazepril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Benazepril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Benazepril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Benazepril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Benazepril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Benazepril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Benazepril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Benazepril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Benazepril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Benazepril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Benazepril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Benazepril.Investigational
Trolamine salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Benazepril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
UnoprostoneBenazepril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Benazepril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Benazepril.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Benazepril.Approved
VerapamilThe risk or severity of adverse effects can be increased when Benazepril is combined with Verapamil.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Benazepril.Approved, Investigational
VincamineBenazepril may increase the hypotensive activities of Vincamine.Experimental
XylometazolineBenazepril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Benazepril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benazepril.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Benazepril.Approved, Investigational, Withdrawn
ZofenoprilBenazepril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Benazepril.Withdrawn
Food Interactions
  • Benazepril may decrease the excretion of potassium. Salt um may increase the risk of hyperkalemia. substitutes containing potassi
  • Food slows absorption without decreasing the quantity absorbed.
  • Herbs that may attenuate the antihypertensive effect of benazepril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of benazepril.
  • Take without regard to meals.

References

Synthesis Reference

Wei-Hong Tseng, "ASYMMETRIC SYNTHESIS OF A KEY INTERMEDIATE FOR MAKING BENAZEPRIL AND ANALOGUES THEREOF." U.S. Patent US20020183515, issued December 05, 2002.

US20020183515
General References
  1. Chan KK, Buch A, Glazer RD, John VA, Barr WH: Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharm Res. 1994 Mar;11(3):432-7. [PubMed:8008712]
  2. De Feo P, Torlone E, Perriello G, Fanelli C, Epifano L, Di Vincenzo A, Modarelli F, Motolese M, Brunetti P, Bolli GB: Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. Diabete Metab. 1992 Jul-Aug;18(4):283-8. [PubMed:1459316]
  3. Gengo FM, Brady E: The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5. [PubMed:1893642]
  4. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. [PubMed:16407508]
  5. Ishimitsu T, Akashiba A, Kameda T, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H: Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology (Carlton). 2007 Jun;12(3):294-8. [PubMed:17498126]
  6. MacNab M, Mallows S: Safety profile of benazepril in essential hypertension. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV33-7; discussion IV51-5. [PubMed:1893640]
  7. Szekacs B, Vajo Z, Dachman W: Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria. Acta Physiol Hung. 1996;84(4):361-7. [PubMed:9328608]
External Links
Human Metabolome Database
HMDB0014682
KEGG Drug
D07499
KEGG Compound
C06843
PubChem Compound
5362124
PubChem Substance
46507884
ChemSpider
4514935
BindingDB
50021153
ChEBI
3011
ChEMBL
CHEMBL838
Therapeutic Targets Database
DAP000584
PharmGKB
PA448561
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Benazepril
ATC Codes
C09AA07 — BenazeprilC09BA07 — Benazepril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (237 KB)
MSDS
Download (57.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealhty1
1CompletedNot AvailableHealthy Volunteers7
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1, 2RecruitingTreatmentHenoch-Schönlein Purpura Nephritis1
2CompletedTreatmentAlport Syndrome1
2RecruitingTreatmentHenoch-Schoenlein Purpura Nephritis2
2TerminatedTreatmentHigh Blood Pressure (Hypertension) / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus (DM)2
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3CompletedTreatmentRenal Alteration1
4CompletedTreatmentAlbuminuria1
4CompletedTreatmentAlbuminuria / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentCongestive Cardiomyopathy1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Proteinuria1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
Not AvailableCompletedTreatmentMicroalbuminuria1
Not AvailableCompletedTreatmentRenal Function Disorder1
Not AvailableTerminatedTreatmentACE Inhibitor / Angiotensin II Type 1 Receptor Blockers / Dose-Response Relationship, Drug / Progression, Disease / Proteinuria / Renal Insufficiency,Chronic1
Not AvailableTerminatedTreatmentChronic Renal Failure (CRF)1
Not AvailableTerminatedTreatmentRenal Insufficiency,Chronic1

Pharmacoeconomics

Manufacturers
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Biokey inc
  • Genpharm inc
  • Huahai us inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Novartis pharmaceuticals corp
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Eon Labs
  • Ethex Corp.
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • International Laboratories Inc.
  • Ivax Pharmaceuticals
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Lupin Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
Dosage forms
FormRouteStrength
CapsuleOral
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
TabletOral10 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral40 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, coatedOral
Tablet, film coatedOral
TabletOral20 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Lotensin 20 mg tablet2.08USD tablet
Lotensin 10 mg tablet2.0USD tablet
Lotensin 40 mg tablet2.0USD tablet
Lotensin 5 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Lotensin 20 mg Tablet1.14USD tablet
Benazepril hcl 10 mg tablet1.07USD tablet
Benazepril hcl 20 mg tablet1.07USD tablet
Benazepril hcl 40 mg tablet1.07USD tablet
Benazepril hcl 5 mg tablet1.07USD tablet
Lotensin 10 mg Tablet0.99USD tablet
Lotensin 5 mg Tablet0.84USD tablet
Apo-Benazepril 20 mg Tablet0.79USD tablet
Apo-Benazepril 10 mg Tablet0.69USD tablet
Apo-Benazepril 5 mg Tablet0.58USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6162802No1997-12-192017-12-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)148.5 °CPhysProp
water solubility2.229 mg/LNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP1.14ALOGPS
logP1.54ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.53ChemAxon
pKa (Strongest Basic)5.36ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.23 m3·mol-1ChemAxon
Polarizability44.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5732
Blood Brain Barrier-0.7082
Caco-2 permeable-0.7279
P-glycoprotein substrateSubstrate0.8466
P-glycoprotein inhibitor IInhibitor0.7426
P-glycoprotein inhibitor IINon-inhibitor0.7565
Renal organic cation transporterNon-inhibitor0.8239
CYP450 2C9 substrateNon-substrate0.7518
CYP450 2D6 substrateNon-substrate0.8563
CYP450 3A4 substrateSubstrate0.5632
CYP450 1A2 substrateNon-inhibitor0.8232
CYP450 2C9 inhibitorNon-inhibitor0.6875
CYP450 2D6 inhibitorNon-inhibitor0.8266
CYP450 2C19 inhibitorInhibitor0.5461
CYP450 3A4 inhibitorInhibitor0.5425
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6038
Ames testNon AMES toxic0.8377
CarcinogenicityNon-carcinogens0.9435
BiodegradationNot ready biodegradable0.9713
Rat acute toxicity2.2082 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Inhibitor0.6696
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ufu-0917700000-5f1f2ae9b1d7afc6eee5

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / Benzazepines / Aralkylamines / Fatty acid esters / Azepines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Amino acids / Lactams
show 8 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / Benzazepine / Alpha-amino acid or derivatives / Azepine / Fatty acid ester / Aralkylamine / Dicarboxylic acid or derivatives / Monocyclic benzene moiety / Fatty acyl
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboxylic acid monoester, ethyl ester, benzazepine (CHEBI:3011)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein complex binding
Specific Function
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name
MTHFR
Uniprot ID
P42898
Uniprot Name
Methylenetetrahydrofolate reductase
Molecular Weight
74595.895 Da
References
  1. Jiang S, Yu Y, Venners SA, Zhang Y, Xing H, Wang X, Xu X: Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7. doi: 10.1038/jhh.2010.50. Epub 2010 May 6. [PubMed:20445573]
  2. Jiang S, Hsu YH, Niu T, Xu X, Xing H, Chen C, Wang X, Zhang Y, Peng S, Xu X: A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study. Clin Exp Hypertens. 2005 Aug;27(6):509-21. [PubMed:16081343]
  3. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu T, Zhang Y, Peng S, Xu X: The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res. 2004;113(6):361-9. [PubMed:15226090]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41